𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation

✍ Scribed by M. van Zonneveld; H. J. Flink; E. Verhey; H. Senturk; S. Zeuzem; U. S. Akarca; Y. Cakaloglu; C. Simon; T. M. K. So; G. Gerken; R. A. de Man; B. E. Hansen; S. W. Schalm; H. L. A. Janssen; The HBV 99-01 Study Group

Book ID
108604063
Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
117 KB
Volume
21
Category
Article
ISSN
0269-2813

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Treatment of chronic hepatitis E in live
Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b
✍ Elizabeth B. Haagsma; Annelies Riezebos-Brilman; Arie P. van den Berg; Robert J. πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 170 KB πŸ‘ 1 views

Hepatitis E virus (HEV) infections are known to run a self-limiting course. Recently, chronic hepatitis E has been described in immunosuppressed patients after solid-organ transplantation. Besides the general recommendation to lower the immunosuppressive medication in these patients, there is curren

Prediction of response to treatment of c
Prediction of response to treatment of chronic hepatitis B with pegylated interferon in the Philippines
✍ Dorothy M. Agdamag; Seiji Kageyama; Prisca S. LeaΓ±o; Rontgene M. Solante; Elizab πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 172 KB πŸ‘ 2 views

## Abstract The response marker for interferon has not been investigated fully for hepatitis B viruses (HBVs) in the Philippines where novel subtypes B5 and C5 were recognized recently. The prediction parameters for interferon treatment were assessed, with emphasis on the mutation patterns in the b